key: cord-0809046-gka6f34c
authors: Jeon, Sangeun; Ko, Meehyun; Lee, Jihye; Choi, Inhee; Byun, Soo Young; Park, Soonju; Shum, David; Kim, Seungtaek
title: Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
date: 2020-06-23
journal: Antimicrob Agents Chemother
DOI: 10.1128/aac.00819-20
sha: 73907e0c70e3d5a1ab2d9b7049fb93f5e6622636
doc_id: 809046
cord_uid: gka6f34c

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.

namely, tilorone, cyclosporine, loperamide, mefloquine, amodiaquine, proscillaridin, digitoxin, digoxin, hexachlorophene, hydroxyprogesterone caproate, salinomycin, ouabain, cepharanthine, ciclesonide, oxyclozanide, anidulafungin, gilteritinib, berbamine, tetrandrine, abemaciclib, ivacaftor, bazedoxifene, niclosamide, and eltrombopag.

Among these 24 drugs, 2 FDA-approved drugs drew our attention. First, niclosamide, an anthelminthic drug, exhibited very potent antiviral activity against SARS-CoV-2 (IC 50 , 0.28 M). Not surprisingly, its broad-spectrum antiviral effect has been (7), including antiviral properties against SARS-CoV and Middle East respiratory syndrome (MERS)-CoV (8, 9) . Recently, Gassen et al. demonstrated that niclosamide inhibits SKP2 activity, which enhances autophagy and reduces MERS-CoV replication (9) . A similar mechanism might be attributable to the inhibition of SARS-CoV-2 infection by niclosamide. Although niclosamide has a pharmacokinetic flaw of low absorption, further development or drug formulation could enable an effective delivery of this drug to the target tissue (10) . Second, ciclesonide is another interesting drug candidate for further development, although its antiviral potency was much lower (IC 50 , 4.33 M) than niclosamide. It is an inhaled corticosteroid used to treat asthma and allergic rhinitis (11) . A recent report by Matsuyama et al. corroborated our finding of ciclesonide as a potential antiviral drug against SARS-CoV-2 (12) . A treatment report of three patients who were infected by SARS-CoV-2 in Japan (13) warrants further clinical investigation of this drug in patients with COVID-19. Intriguingly, an underlying mechanism for the suppression of viral infection by ciclesonide has been revealed by the isolation of a drug-resistant mutant (12) . The isolation of the drug-resistant mutant indicated that NSP15, a viral endoribonuclease, is the molecular target of ciclesonide. Together, these findings suggest that it is not unreasonable to consider that ciclesonide exhibits direct-acting antiviral activity in addition to its intrinsic anti-inflammatory function. In the future, small interfering RNA (siRNA) targeting the hormone receptor will allow for an assessment of the extent Prior to our evaluation of 48 drugs against SARS-CoV-2 infection, we also tested the antiviral activity of several other drugs based on the cytopathic effect of the virus in the presence of each drug (Fig. 2) . In particular, the effects of favipiravir and atazanavir on SARS-CoV-2 were compared with those of the reference drugs (chloroquine, lopinavir, and remdesivir) because favipiravir is considered a drug candidate for clinical trials and atazanavir was recently predicted as the most potent antiviral drug by artificial intelligence (AI)-inference modeling (14) . However, in the current work, we did not observe any antiviral activity of either favipiravir or atazanavir.

In summary, we selected and screened 48 FDA-approved drugs based on our SARS-CoV screening, and our screening campaign revealed 24 potential antiviral drug candidates against SARS-CoV-2. Our findings could be further validated in an appropriate animal model and, hopefully, developed through subsequent clinical trials in order to provide additional therapeutic options for patients with COVID-19.

Virus and cells. Vero cells were obtained from the American Type Culture Collection (ATCC CCL-81) and maintained at 37°C with 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM; Welgene), supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1ϫ antibiotic-antimycotic solution (Gibco). SARS-CoV-2 (␤CoV/KOR/ KCDC03/2020) was provided by Korea Centers for Disease Control and Prevention (KCDC) and was propagated in Vero cells. Viral titers were determined by plaque assays in Vero cells. All experiments using SARS-CoV-2 were performed at Institut Pasteur Korea in compliance with the guidelines of the Korea National Institute of Health (KNIH), using enhanced biosafety level 3 (BSL3) containment procedures in laboratories approved for use by the KCDC.

Reagents. Chloroquine diphosphate (CQ; C6628) was purchased from Sigma-Aldrich (St. Louis, MO), lopinavir (LPV; S1380) was purchased from SelleckChem (Houston, TX), and remdesivir (HY-104077) was purchased from MedChemExpress (Mon- The acquired images were analyzed using in-house software to quantify cell numbers and infection ratios, and antiviral activity was normalized to positive (mock) and negative (0.5% DMSO) controls in each assay plate. DRCs were fitted by sigmoidal dose-response models, with the following equation: Y ϭ bottom ϩ (top Ϫ bottom)/[1 ϩ (IC 50 /X) Hillslope ], using XLfit 4 software or Prism7. IC 50 values were calculated from the normalized activity data set-fitted curves. All IC 50 and 50% cytotoxic concentration (CC 50 ) values were measured in duplicate, and the quality of each assay was controlled by Z'-factor and the coefficient of variation in percent (%CV).

DRC analysis by CPE. Ten-point DRCs were generated for each drug. Vero cells were seeded at 1.2 ϫ 10 4 cells per well in DMEM, supplemented with 2% FBS and 1ϫ antibiotic-antimycotic solution (Gibco) in white, 384-well Clear plates (Greiner Bio-One) 24 h prior to the experiment. Ten-point DRCs were generated, with compound concentrations ranging from 0.1 to 50 M. For the viral infections, plates were transferred into the BSL3 containment facility and SARS-CoV-2 was added at a multiplicity of infection (MOI) of 0.05 and incubated at 37°C for 72 h. Cell viability was measured using the CellTiter-Glo luminescent cell viability assay (Promega), according to the manufacturer's instructions. Antiviral activity was determined by the degree of inhibition of viral cytopathic effect (CPE). The results were normalized to positive (mock) and negative (0.5% DMSO) controls in each assay plate. DRCs were fitted by sigmoidal dose-response models, with the following equation: Y ϭ bottom ϩ (top Ϫ bottom)/ [1 ϩ (IC 50 /X) Hillslope ], using XLfit 4 software or Prism7. IC 50 values were calculated from the normalized activity data set-fitted curves. All IC 50 and CC 50 values were measured in duplicate, and the quality of each assay was controlled by Z'-factor and the coefficient of variation in percent (%CV).

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Estimating the risk of 2019 novel coronavirus death during the course of the outbreak in China

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Drug repositioning: identifying and developing new uses for existing drugs

More than 80 clinical trials launch to test coronavirus treatments

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Broad spectrum antiviral agent niclosamide and its therapeutic potential

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection

Absorption of pyrvinium pamoate

Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: report of three cases

through a drug-target interaction deep learning model

We thank Wang-Shick Ryu and Spencer Shorte for their helpful discussion and review of the manuscript. The pathogen resource (NCCP43326) for this study was provided by the National Culture Collection for Pathogens. This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2017M3A9G6068245 and NRF-2020M3E9A1041756).